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Abstract
Prostaglandin E2 plays important roles in the maintenance of colonic homeostasis. The
recently identified prostaglandin E receptor (EP) 4–associated protein (EPRAP) is essential
for an anti-inflammatory function of EP4 signaling in macrophages in vitro. To investigate
the in vivo roles of EPRAP, we examined the effects of EPRAP on colitis and colitis-associ-
ated tumorigenesis. In mice, EPRAP deficiency exacerbated colitis induced by dextran
sodium sulfate (DSS) treatment. Wild-type (WT) or EPRAP-deficient recipients transplanted
with EPRAP-deficient bone marrow developed more severe DSS-induced colitis than WT
or EPRAP-deficient recipients of WT bone marrow. In the context of colitis-associated
tumorigenesis, both systemic EPRAP null mutation and EPRAP-deficiency in the bone mar-
row enhanced intestinal polyp formation induced by azoxymethane (AOM)/DSS treatment.
Administration of an EP4-selective agonist, ONO-AE1-329, ameliorated DSS-induced coli-
tis in WT, but not in EPRAP-deficient mice. EPRAP deficiency increased the levels of the
phosphorylated forms of p105, MEK, and ERK, resulting in activation of stromal macro-
phages in DSS-induced colitis. Macrophages of DSS-treated EPRAP-deficient mice exhib-
ited a marked increase in the expression of pro-inflammatory genes, relative to WT mice. By
contrast, forced expression of EPRAP in macrophages ameliorated DSS-induced colitis
and AOM/DSS-induced intestinal polyp formation. These data suggest that EPRAP in mac-
rophages functions crucially in suppressing colonic inflammation. Consistently, EPRAP-
positive macrophages were also accumulated in the colonic stroma of ulcerative colitis
patients. Thus, EPRAPmay be a potential therapeutic target for inflammatory bowel dis-
ease and associated intestinal tumorigenesis.
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Author Summary
Inflammatory bowel disease (IBD) is one of the most prevalent and serious gastrointestinal
diseases inWestern countries and associates with cancer development. EP4 receptor signaling
can suppress intestinal inflammation and shows promise as a target for the development of
novel therapies for IBD. To date, however, the lack of detailed molecular targets has hampered
the development of effective drugs. This study focused on EPRAP, a novel EP4 receptor–asso-
ciated protein, implicated in its signaling pathway. The generation of EPRAP-gene mutated
mice permitted exploration of EPRAP functions in vivo. In addition, EPRAP was localized in
stromal macrophages of ulcerative colitis patients. This study revealed that EPRAP in macro-
phage participates critically in EP4 receptor signaling-mediated inhibition of intestinal inflam-
mation. The macrophage EP4–EPRAP axis thus comprises a novel therapeutic target for IBD.
Introduction
The incidence of inflammatory bowel disease (IBD) is increasing, and current concepts attri-
bute IBD to inappropriate chronic inflammatory responses to commensal microbes in geneti-
cally susceptible patients [1]. Prostaglandin E2 (PGE2) plays a pivotal role in maintaining local
homeostasis in a variety of pathophysiological settings. PGE2 receptors (EPs) mediate the
effects of this molecule and include four subtypes: EP1–4 [2]. PGE2 participates decisively in
the defense of the colonic mucosa. For example, misoprostol, a synthetic PGE1 analog, potently
protects human colonic mucosa against mucosal insults [3]. In addition, in mice, PGE2 and
EP4-selective agonists significantly improved colitis induced by dextran sodium sulfate (DSS)
treatment [4,5]. Yet, misoprostol frequently induces severe diarrhea in humans [6], and treat-
ment with EP receptor agonists can induce vasodilatation, causing hypotension [7]. Indeed, in
a phase 2 clinical trial of an EP4-selective agonist for ulcerative colitis patients, diarrhea or
hypotension occurred in patients with EP4 agonist treatment [8]. These undesired effects of
PGE2 and EP4 agonists likely result from increased cAMP production in colonic or vascular
endothelial cells. Hence the need is urgent to develop molecules that stimulate EP4 receptors
but have fewer side effects to treat IBD, and potentially other inflammatory diseases.
EPRAP, a cytoplasmic EP4–interacting molecule, emerged from yeast two-hybrid screening,
using the C-terminus of EP4 receptor as a bait [9]. EPRAP contains multiple ankyrin repeat
motifs, but has no predicted enzymatic or catalytic domain. EPRAP transcripts abound in the
heart, skeletal muscle, and the kidney, and localize at lower amounts in several other human
tissues [10]. The counterpart of EPRAP in mice is Fem1a, a mammalian ortholog of Caenor-
habditis elegans FEM-1. FEM-1 participates in nematode sex determination [11], although the
functions of mouse EPRAP/Fem1a and of human EPRAP remain uncertain.
In vitro, EPRAP in macrophages mediates an anti-inflammatory function of PGE2–EP4 sig-
naling [12]; however, the pathophysiological roles of EPRAP in colonic inflammation in vivo
remain unknown. In this study, we evaluated the role of EPRAP in the development of colitis
and colitis-associated tumorigenesis using EPRAP-deficient mice and macrophage-specific
EPRAP-overexpressing mice.
Results
EPRAP deficiency exacerbates DSS-induced colitis
The generation of mice lacking the gene encoding EPRAP enabled investigation of the role of
EPRAP in colonic inflammation (S1 Fig). EPRAP-deficient mice were fertile and grew
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normally without apparent malformation. DSS-induced colitis is a widely used rodent model
of human IBD [13]. After the administration of 2.5% DSS for 5 days and regular water for the
following 16 days, EPRAP-deficient mice exhibited significantly higher mortality (Fig 1A) and
markedly lower body weight (Fig 1B) relative to WT mice. In addition, EPRAP-deficient mice
had reduced colon length (Fig 1C and 1D). Histopathologically, EPRAP-deficient mice treated
with DSS exhibited more prominent crypt loss, as well as elevated infiltration by inflammatory
cells: DSS-treated EPRAP-deficient mice had significantly higher histological damage scores
[14] than did WTmice (Fig 1E and 1F). The colons of DSS-treated EPRAP-deficient mice
showed significantly elevated accumulation of macrophages, neutrophils, B cells, CD4+ T cells,
or CD8+ T cells (Figs 1G and S2A). Furthermore, the colons of DSS-treated EPRAP-deficient
mice contained markedly higher levels of pro-inflammatory cytokines and chemokines such as
TNF-α, IL-1β, IL-6, CXCL1, and MCP-1 compared to controls (Fig 1H). Markers for classically
activated macrophages such as iNOS and CXCL10 also increased in EPRAP-deficient mice
(S2B Fig). Thus, the colonic mucosa of EPRAP-deficient mice showed accentuated inflamma-
tory damage caused by DSS treatment.
Fig 1. EPRAP deficiency exacerbates DSS-induced colitis and adenoma formation after AOM/DSS treatment. (A) Survival curves during the DSS
treatment. Elevated mortality was observed in EPRAP-deficient (KO) mice, relative to WT (n = 18 each, *P < 0.01). (B) Percent changes in body weight
(n = 16 [WT]; n = 17 [KO]). (C) Representative photographs of colons from each group. (D) Percent changes in colon length in WT and KOmice (n = 8 [WT];
n = 5 [KO]) in comparison to those of mice received DSS-free water. (E) Histological colitis scores (n = 10 each). (F) Representative H&E staining of rectal
sections. (G) The numbers of F4/80-, Gr-1–, B220-, CD4-, and CD8-positive cells infiltrated in colonic tissues per high-power field (400× magnification) (n = 8
each). (H) The expression levels of TNF-α, IL-1β, IL-6, CXCL1, and MCP-1 protein in colonic tissue extracts from DSS-treated WT and KOmice (n = 15 [WT];
n = 9 [KO]). (I) Survival curves during the AOM/DSS treatment (n = 18 [WT]; n = 22 [KO], P < 0.05). (J) The number of colonic tumors per mouse, with size
distribution (left) and total number (right) in AOM/DSS-treated WT and KOmice (n = 9 [WT]; 8 [KO]). (K) Representative photographs of colons at the end of
AOM/DSS treatment. (L) Ki-67–positive cells in rectal polyps of AOM/DSS-treatedWT and KOmice (left). KOmice exhibited greater numbers of Ki-67–
positive cells thanWTmice (right) (n = 5 each). (M) TUNEL assays on polyps of AOM/DSS-treatedWT and KOmice. The arrows point to TUNEL-positive
apoptotic cells: the insets show higher magnifications of selected regions (indicated by dashed boxes) (left). KOmice exhibited fewer TUNEL-positive cells
thanWTmice (right) (n = 5 each). All values represent means ± SEM. *P < 0.05, **P < 0.01 vs. WTmice. Scale bars: 100 μm.
doi:10.1371/journal.pgen.1005542.g001
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EPRAP deficiency enhances polyp formation after AOM/DSS treatment
Colitis-associated tumorigenesis associates closely with the duration and severity of colonic
inflammation [15]. Because EPRAP-deficient mice had more prominent colitis induced by
DSS, we tested the hypothesis that EPRAP reduces colitis-associated tumorigenesis. WT and
EPRAP-deficient mice were intraperitoneally injected with AOM, followed by three cycles of
5-day administration of 2% DSS. After this treatment, EPRAP-deficient mice exhibited a signif-
icantly higher mortality rate than WTmice (Fig 1I), with more prominent crypt loss and ele-
vated histological damage scores (S3A and S3C Fig). The colons of AOM/DSS-treated EPRAP-
deficient mice showed significantly increased accumulation of inflammatory cells including
macrophages, neutrophils, B cells, CD4+ T cells, or CD8+ T cells (S3B and S3D Fig). Concomi-
tantly, EPRAP-deficient mice developed a significantly greater number of colonic polyps at day
63 (Fig 1J and 1K). Furthermore, tumors of EPRAP-deficient mice had more Ki-67–positive
(Fig 1L), but fewer TUNEL-positive cells, than those of WT mice (Fig 1M), indicating that
EPRAP, either directly or indirectly, suppressed cell proliferation and promoted apoptosis dur-
ing colitis-associated tumor development.
EPRAP in bone marrow–derived cells attenuates colitis and colitis-
induced tumorigenesis
To determine which EPRAP-deficient cells contribute to the suppression of colitis and associ-
ated tumorigenesis, we used four kinds of chimeric mice generated by bone marrow transplan-
tation. Following DSS treatment, WT and EPRAP-deficient recipients of EPRAP-deficient
bone marrow exhibited greater colon shortening, crypt loss, content of inflammatory cells, and
a higher histological damage score than WT or EPRAP-deficient recipients of WT bone mar-
row (Fig 2A–2D). Similarly, after AOM/DSS treatment, WT or EPRAP-deficient recipients of
EPRAP-deficient bone marrow developed significantly more polyps (Fig 2E and 2F) than
recipients of WT bone marrow. These observations indicated that EPRAP-expressing bone
marrow cells predominated over epithelial cells in suppression of DSS-induced colitis and of
AOM/DSS-induced tumorigenesis. In agreement with these in vivo findings in mice, human
colon cancer cell lines with gain or loss of function of human EPRAP (S4 Fig) also showed that
EPRAP expression did not affect cell proliferation (Fig 2G).
Macrophages express EPRAP which suppresses their activation
Normal colonic tissues of WT mice showed negligible immunoreactive EPRAP; however, not
epithelial cells but mononuclear cells in lamina propria and submucosal regions in the colonic
tissues of DSS- or AOM/DSS-treated WT mice displayed abundant EPRAP (S5A and S5G Fig).
Double-color immunofluorescence analyses revealed predominent EPRAP protein in F4/
80-positive macrophages (S5B Fig), but not in CD4+ T cells, CD8+ T cells, dendritic cells, B
cells, or NK cells (S5C Fig). Neutrophils also contained EPRAP (S5D Fig); however, EPRAP
deficiency did not alter myeloperoxidase activity in the colonic tissues of DSS-treated mice
(S5E Fig), suggesting that EPRAP deficiency in neutrophils does not play a major role in
enhancing colitis and colitis-associated tumorigenesis. We further isolated lamina propria
macrophages from DSS-treated mice by flow cytometry, and measured mRNAs that encode
pro-inflammatory cytokines and chemokines by quantitative PCR. Lamina propria macro-
phages of EPRAP-deficient mice exhibited marked increases in the mRNAs corresponding to
TNF-α, IL-1β, IL-6, CXCL1, and MCP-1 relative to those of WT mice (S5F Fig), indicating that
EPRAP contributes critically to inhibiting macrophage activation and colonic inflammation.
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Fig 2. EPRAP in bonemarrow–derived cells attenuates colitis and colitis-induced tumorigenesis.
Four kinds of chimeric mice were generated by adoptive bone marrow transplantation: (A) Representative
photographs of colons with adoptive bone marrow transplantation. (B) Percent changes in colon length
expressed relative to DSS-free water controls in each group. (n = 4–8 each). (C) Histological colitis scores
(n = 4–8 each). (D) Representative H&E staining of rectal sections. Scale bars: 100 μm. (E)Representative
photographs of colons at the end of AOM/DSS treatment. (F) The number of colonic tumors per mouse, with
the size distribution (left) and the total number (right) in each group (n = 4–9 each). (G) EPRAP did not directly
affect cell proliferation. DLD-1 cell proliferation was determined by MTS assay (over expression of EPRAP,
left; knockdown of EPRAP, right). Data represent fold induction of absorbance compared with mock or
negative control. All values represent means ± SEM. *P < 0.05, **P < 0.01.
doi:10.1371/journal.pgen.1005542.g002
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EPRAP deficiency impairs the anti-inflammatory effect of PGE2–EP4
signaling
EPRAP contributes to PGE2/EP4-mediated inhibition of inflammation of macrophages in vitro
[12]. To determine whether EPRAP alters anti-inflammatory functions of EP4 signaling in
vivo, we examined the pharmacological effects of ONO-AE1-329, a selective EP4 agonist, in
DSS-induced colitis of WT and EPRAP-deficient mice. Administration of ONO-AE1-329 sig-
nificantly decreased colon shortening, crypt loss, infiltration of inflammatory cells, and histo-
logical damage score in WT mice with DSS-induced colitis (Fig 3A–3D). In contrast, the EP4
agonist did not protect EPRAP-deficient mice from DSS-induced colitis, indicating that EP4
signaling improved colitis through EPRAP. Consistent with the results of previous in vitro
experiments [12], administration of EP4 agonist decreased the phosphorylation of MEK and
ERK in the stromal macrophages of DSS-treated WT but not EPRAP-deficient mice (S6 Fig).
EP4 activation increases intracellular levels of cAMP, a major downstream effector of EP4
Fig 3. EPRAP deficiency impairs the anti-inflammatory effect of PGE/EP4. (A) Representative
photographs of colons; “Veh” indicates vehicle and “EP4” indicates EP4 agonist. (B) Percent changes in
colon length expressed relative to DSS-free water controls (n = 5–8 each; **P < 0.01 vs. WT + Veh). (C)
Histological colitis scores (n = 5–8 each; *P < 0.05 vs. WT + Veh). (D) Representative H&E staining. Scale
bars: 100 μm. (E, F) Peritoneal macrophages (E) and colonic epithelial cells (F) isolated fromWT and KO
mice were incubated with EP4 agonist. Intracellular cAMP levels were measured as described in
Supplemental Methods (*P < 0.05 and **P < 0.01 vs. 0 μM). Figures are representative of five independent
experiments performed in triplicate. (G, H) EP4 mRNA levels in peritoneal macrophages (G) and colonic
epithelial cells (H) fromWT and KOmice (n = 6 each). Data represent fold induction of mRNA expression
compared with WT. All values represent means ± SEM.
doi:10.1371/journal.pgen.1005542.g003
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signaling. To test the involvement of EPRAP in the cAMP increase resulting from EP4 activa-
tion, we measured the levels of cAMP in peritoneal macrophages and colonic epithelial cells
obtained fromWT and EPRAP-deficient mice, with or without ONO-AE1-329 treatment.
Cyclic AMP production induced by the EP4 agonist in both peritoneal macrophages (Fig 3E)
and colonic epithelial cells (Fig 3F) did not differ significantly between WT and EPRAP-defi-
cient mice. Furthermore, neither cell type showed a significant difference in the level of EP4
mRNA (Fig 3G and 3H). These data suggested that the anti-inflammatory function of EP4–
EPRAP pathway does not involve cAMP increase.
EPRAP inhibited p105 phosphorylation and MEK-ERK activation in
stromal macrophages
Via a direct interaction, EPRAP suppresses stimulus-induced phosphorylation and subsequent
degradation of NF-κB1 p105, resulting in the inhibition of MEK and ERK activation in macro-
phages [12]. Study of WT and EPRAP-deficient mice affirmed that lacking EPRAP enhanced
LPS-induced phosphorylation of p105, MEK and ERK (S7A and S7B Fig), with elevated
mRNA production of TNF-α, IL-1β, IL-6, and CXCL1 (S7C Fig) in peritoneal macrophages in
vitro. Pretreatment with the MEK inhibitor cancelled the increased expression of those pro-
inflammatory molecules, indicating that EPRAP deficiency in macrophages causes unopposed
MEK activation and subsequent inflammatory responses induced by LPS (S7D Fig). Indeed,
phosphorylation levels of MEK increased significantly in inflamed colons isolated from
EPRAP-deficient mice compared to those of WT mice following DSS treatment (Fig 4A). To
corroborate EPRAP participation in this pathway in the context of DSS-induced colitis, we
assessed the levels of the phosphorylated forms of p105, MEK, and ERK in stromal macro-
phages by immunohistochemistry and flow cytometry. Double-color immunofluorescence
analyses demonstrated more prominent phosphorylated forms of p105, MEK, and ERK in the
stromal macrophages of EPRAP-deficient mice than in those of WT mice (Fig 4B and 4C).
Flow-cytometric analyses with lamina propria macrophages isolated from colitis lesions
yielded similar results (Fig 4D): mean fluorescence intensity (MFI) indicated that the intracel-
lular levels of the phosphorylated forms of each molecule varied inversely with the levels of
EPRAP expression in macrophages. These observations suggested that EPRAP suppressed coli-
tis through its interaction with NF-κB1 p105, thereby limiting the activation of the MEK–ERK
MAPK pathway in stromal macrophages.
EPRAP overexpression in macrophages suppresses colitis and colitis-
associated tumorigenesis
To verify the pivotal role of EPRAP in macrophages, we generated transgenic mice in which
the murine CD68 promoter directed murine EPRAP expression (CD68–mEPRAP transgenic
mice), leading to overexpression of EPRAP selectively in macrophages (S8 Fig). CD68–
mEPRAP transgenic mice were fertile, accumulated body weight normally, and did not develop
spontaneous diarrhea. During the course of DSS-induced colitis, WT and CD68–mEPRAP
transgenic mice had no significant difference in mortality or body weight loss (S9A and S9B
Fig); however, CD68–mEPRAP transgenic mice showed markedly reduced colon shortening
(Fig 5A and 5B). Histological examination of the colon obtained from DSS-treated CD68–
mEPRAP transgenic mice revealed reduced crypt loss and fewer inflammatory cells than in
colons of WT mice (Fig 5C and 5D). Indeed, DSS-treated CD68–mEPRAP transgenic mice,
had fewer neutrophils, B cells, CD4+ T cells, and CD8+ T cells as well as macrophages (Figs 5E
and S9C), and reduced concentrations of TNF-α, IL-1β, IL-6, CXCL1, or MCP-1 (Fig 5F). As
well, after 3 cycles of DSS treatment following intraperitoneal AOM injection, CD68–mEPRAP
EPRAP in Macrophage Inhibits Colonic Inflammation
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transgenic mice also exhibited less crypt loss, decreased infiltration of inflammatory cells with
lower histological damage scores than WTmice (S10 Fig). In colitis-associated tumorigenesis,
in contrast to WT mice, all CD68–mEPRAP transgenic mice survived the AOM/DSS treatment
(Fig 5G), and CD68–mEPRAP transgenic mice developed fewer polyps (Fig 5H and 5I). In
addition, polyps of CD68–mEPRAP transgenic mice contained significantly fewer Ki-67–
Fig 4. EPRAP inhibits p105 phosphorylation and MEK–ERK activation in stromal macrophages with DSS treatment. (A) The expression levels of
Akt1, and phosphorylated forms of either Akt1, MEK1, p38MAPK, Stat3 or NF-κB p65 in colonic tissue extracts from DSS-treated KOmice compared to WT
mice (n = 9 [WT]; n = 7 [KO]). (B) Double-color immunofluorescence analyses of rectal sections from DSS-treated WT, EPRAP-deficient (KO), and CD68–
mEPRAP transgenic (TG) mice. Samples were immunostained with anti-F4/80 (green) and anti–phospho-p105 (red, top), anti–phospho-MEK (red, middle),
or anti–phospho-ERK (red, bottom) antibodies. Scale bars: 20 μm. (C) The percentages of stained cells in F4/80 positive cells. (n = 5 each). (D) Lamina
propria macrophages were isolated from the colonic tissues of WT, KO, and TGmice with DSS treatment. Cells were analyzed by flow cytometry, with
detection of phospho-p105 (top), phospho-MEK (middle), or phospho-ERK (bottom) (open histograms). Cells were also stained with isotype control
antibodies (solid histograms). Figures are representative histograms performed in quintuplicate (left). The levels of phosphorylated forms of p105 (top), MEK
(middle), and ERK (bottom) in viable cells fromWT, KO, and TGmice were determined as the geometric mean fluorescence intensity (MFI) of the target
antibody minus the MFI of the isotype control (right) (n = 5 each). All values represent means ± SEM. **P < 0.01 vs. WTmice.
doi:10.1371/journal.pgen.1005542.g004
EPRAP in Macrophage Inhibits Colonic Inflammation
PLOS Genetics | DOI:10.1371/journal.pgen.1005542 October 6, 2015 8 / 20
positive cells (Fig 5J), but more TUNEL-positive cells, than those of WT mice (Fig 5K). These
results indicated that forced expression of EPRAP in macrophages suppressed colitis and coli-
tis-associated tumorigenesis.
Regarding the impact of EPRAP overexpression in macrophages on p105 phosphorylation
and MEK–ERK activation, double-color immunofluorescence analyses demonstrated less
phosphorylation of these molecules in stromal macrophages of CD68–mEPRAP transgenic
mice with DSS treatment than in those of WT mice (Fig 4B and 4C). Flow-cytometric analyses
with lamina propria macrophages isolated from colitis lesions yielded similar results (Fig 4D).
EPRAP-positive macrophages were accumulated in the colon of
ulcerative colitis patients
To examine the role of EPRAP on human IBD pathogenesis, we immunostained EPRAP in
resected colonic specimens of ulcerative colitis (UC) patients. Normal colonic specimens obtained
from another cohort showed few EPRAP-positive mononuclear cells; however, mononuclear cells
Fig 5. EPRAP overexpression in macrophages ameliorates DSS-induced colitis and colitis-associated tumorigenesis. (A) Representative
photographs of colons at the end of DSS treatment; colons were obtained fromWT and CD68–mEPRAP transgenic (TG) mice. (B) Percent changes in colon
length expressed relative to DSS-free water controls (n = 8 [WT]; n = 6 [TG]). (C) Histological colitis scores (n = 10 [WT]; n = 8 [TG]). (D) Representative H&E
staining of rectal sections. (E) The numbers of F4/80-, Gr-1–, B220-, CD4-, and CD8-positive cells infiltrated in colonic tissues of WT and TGmice, per high-
power field (400× magnification) (n = 8 each). (F) The expression levels of TNF-α, IL-1β, IL-6, CXCL1, and MCP-1 protein in colonic tissue lysates from DSS-
treatedWT and TGmice (n = 15 [WT]; n = 8 [TG]). (G) Survival curves during the course of AOM/DSS treatment in WT and TGmice (n = 18 [WT]; n = 11 [TG];
P < 0.05). (H) The numbers of colonic polyps per mouse, with size distribution (left) and total number (right) in colonic tissues of AOM/DSS-treatedWT and
TGmice (n = 9 [WT]; n = 10 [TG]). (I) Representative photographs of colons at the end of AOM/DSS treatment. (J) Ki-67–positive cells in rectal polyps of
AOM/DSS-treatedWT and TGmice (left). TGmice exhibited markedly fewer Ki-67–positive cells thanWTmice (n = 5 each) (right). (K) Representative
photographs of TUNEL assay performed on rectal polyps of AOM/DSS-treatedWT and TGmice. The arrows indicate TUNEL-positive apoptotic cells: the
insets show higher magnifications of selected regions (indicated by dashed boxes) (left). TGmice exhibited more TUNEL-positive cells thanWTmice (right)
(n = 5 each). All values represent means ± SEM. *P < 0.05, **P < 0.01 vs. WTmice. Scale bars: 100 μm.
doi:10.1371/journal.pgen.1005542.g005
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in lamina propria in the colonic tissues of UC patients displayed a large number of EPRAP-posi-
tive cells (Fig 6A and 6B). Double-color immunofluorescence analyses suggested those EPRAP-
positive cells are stromal macrophages (Fig 6B). Notably, there was an inverse relationship
between the percentage of EPRAP-positive cells in stromal macrophages and the disease severity
of the UC patients (Fig 6C), suggesting that inflammatory stimuli could induce EPRAP-positive
macrophages to mitigate excess local immune responses; and less EPRAP expression in macro-
phages may cause more severe intestinal inflammation. Accordingly, phosphorylations or activa-
tions of p105, MEK and ERK were more prominent in EPRAP-negative mononuclear cells in
lamina propria of human UC samples (S11 Fig).These data are consistent with DSS- or AOM/
DSS-treated mouse colon, and suggest that EPRAP plays roles in human IBD.
Discussion
Our previous studies showed that EPRAP, a novel EP4 receptor interactor, mediates the anti-
inflammatory actions of EP4 in macrophages [9,12]. This study demonstrated that EPRAP
expression is elevated in the stromal macrophages of both mouse and human colitis, and that
EPRAP participates critically in suppressing colonic inflammation. Systemic or bone marrow–
specific deficiency of EPRAP exacerbated DSS-induced colitis and increased AOM/DSS-
induced polyp formation. In contrast, forced expression of EPRAP in macrophages or trans-
plantation of EPRAP-sufficient bone marrow into EPRAP-deficient mice ameliorated these
endpoints. Improvement of DSS-induced colitis by EP4 agonist administration required
EPRAP, whereas cAMP, a downstream mediator of EP4, did not appear to contribute to the
anti-inflammatory effect of EPRAP in the colon.
In mice treated with either DSS or AOM/DSS, EPRAP participated essentially in the regula-
tion of pro-inflammatory gene expression and accumulation of inflammatory cells during
mucosal inflammation and tumorigenesis. IBD associates with the development of colonic can-
cer [16], and EPRAP appeared to suppress colonic tumorigenesis indirectly by attenuating
mucosal inflammation.
To determine which cell types are responsible for the suppression of colonic inflammation
and tumorigenesis, we first examined cell proliferation assays using human colon cancer cell
Fig 6. The colons of ulcerative colitis (UC) showed accumulation of EPRAP-positive macrophages.
(A) Immunohistochemical staining for EPRAP in the sections of normal human and UC colons: the insets
show higher magnifications of selected regions (indicated by dash boxes). Scale bars: 100 μm. (B) Double-
color immunofluorescence analyses using sections of normal and UC colons were performed with anti-CD68
(green) and anti–EPRAP (red) antibodies (left). Scale bars: 20 μm. The percentage of EPRAP-positive cells
in CD68-positive cells (right) (n = 20 [normal]; n = 20 [UC]). **P < 0.01 vs. normal colons. (C) Relationship
between the percentage of EPRAP positive cells in CD68-positive macrophages and the clinical severity of
UC patients (mild to moderate vs. severe) (n = 22 [mild to moderate]; n = 16 [severe]). *P < 0.05.
doi:10.1371/journal.pgen.1005542.g006
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lines; however, EPRAP expression levels did not affect cell proliferation, suggesting that
EPRAP does not play a role in epithelial or tumor cells. Consistent with this, EPRAP was not
detectable by immunohistochemistry in colonic epithelial cells or lamina propria cells in the
absence of inflammation; once these tissues were inflamed, however, lamina propria and sub-
mucosal inflammatory cells such as macrophages expressed EPRAP abundantly. Bone marrow
transplantation experiments determined that EPRAP-expressing cells from this source medi-
ated the reduction in bowel inflammation and a pivotal role for EPRAP-expressing cells in the
stroma. Systemic or bone marrow-specific deficiency of EPRAP exacerbated colitis and colonic
tumorigenesis; in contrast, forced expression of EPRAP in macrophages or restoration of
EPRAP expression in bone marrow cells reversed these findings. Thus, EPRAP expression in
macrophages mediates the suppression of inflammation and tumorigenesis in the colon.
In DSS-treated WTmice, neutrophils as well as macrophages in the colon expressed
EPRAP. In human IBD, activated neutrophils accumulated within epithelial crypts produce
reactive oxygen species, which induces oxidative stress and mucosal injury [17]; however, in
this study, EPRAP deficiency did not affect myeloperoxidase activity, a marker for neutrophil
oxidative stress. These data support the conclusion that EPRAP in macrophages, rather than in
neutrophils, is critical for the suppression of colonic inflammation and tumorigenesis.
EP4 signaling attenuates colonic inflammation in mouse models of human IBD [4,5]. EP4
participates not only in reducing accumulation of macrophages but also in suppressing prolif-
eration and activation of CD4+ T cells [5]. This study showed that the protective effect of an
EP4 agonist against DSS-induced colitis depended largely on EPRAP. After DSS treatment,
inflammatory cells as well as in colonic epithelial cells express EP4 [18]. Downstream of EP4,
intracellular cAMP mediates many of the biological effects of EP4 signaling. For example, ele-
vation of intracellular cAMP after EP receptor activation contributes to the defense of the gas-
trointestinal mucosa by stimulating mucin secretion from epithelial cells and regulating local
immune responses [19,20]. Meanwhile, excessive secretion of mucin induced by the cAMP
pathway promotes diarrhea. Furthermore, augmentation of intracellular cAMP by EP4 stimu-
lation in vascular endothelial cells induces vasodilatation, evoking hypotension [7]. In this
regard, the deletion of EPRAP affected neither the reduction in intracellular cAMP production
mediated by EP4 activation nor EP4 expression. These results agree with our previous in vitro
studies that showed that the anti-inflammatory effect of EP4–EPRAP in macrophages did not
depend on intracellular cAMP [9,12]. Taken together, these data identify EPRAP signaling in
macrophages as a target for IBD therapies that would avoid known unwanted actions of EP4
agonism in inflammatory diseases.
This study dissected the molecular mechanisms by which EPRAP suppresses colonic
inflammation. Via a direct interaction, EPRAP in cultured macrophages inhibits stimulus-
induced phosphorylation and subsequent degradation of NF-κB1 p105, thereby suppressing
MAPK activation [12]. Indeed, NF-κB1 p105 is an important scaffold protein in MAPK signal-
ing: p105 binds to tumor progression locus-2 (TPL2), a mitogen-activated protein kinase, and
inhibits kinase activity [21]. In response to inflammatory stimulation, IκB kinase (IKK) com-
plex phosphorylates p105, leading to proteolytic degradation of p105 and subsequent release of
TPL2 [22]. TPL2 then directly phosphorylates and activates MEK, followed by phosphoryla-
tion and activation of ERK. ERK, a MAPK, phosphorylates a number of target proteins, and
critically regulates pro-inflammatory activation in colitis and colitis-associated tumorigenesis
[23]. Indeed, mice lacking the p105/p50 subunit have heightened susceptibility to colitis
induced byHelicobacter hepaticus infection [24]. In addition, previous kinetic analyses using
cell lysates from intestinal mucosa of IBD patients indicated marked acceleration of ATP-
dependent degradation of p105 occurs in the presence of proteasomes from IBD patients [25].
This study demonstrated that EPRAP deficiency increased the proportions of the
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phosphorylated forms of p105, MEK, and ERK in stromal macrophages in DSS-induced colitis,
whereas forced EPRAP expression had the opposite effect. In particular, EPRAP impaired the
activation of MEK–ERKMAPK pathway, likely through p105, thereby decreasing the produc-
tion of pro-inflammatory cytokines and chemokines in stromal macrophages and ultimately
inhibiting colonic inflammation.
In summary, EPRAP in macrophages mediates attenuation of colonic inflammation by
PGE2–EP4, and these functions do not depend on cAMP production. EPRAP in macrophages
also suppressed tumorigenesis. These data identify EPRAP as a promising target for the treat-
ment of IBD patients.
Materials and Methods
Ethics statement
All animal care and experiments were conducted following the guidelines for the Japan’s Act
onWelfare and Management of Animals. The study protocol was approved by the Institutional
Animal Care and Use Committees (IACUC)/ethics committee of Kyoto University. All surgery
was performed when mice were anesthetized by 40 mg/kg of pentobarbital sodium (Kyoritsu
Seiyaku, Tokyo, Japan), and all efforts were made to minimize suffering.
For immunohistochemistry of human samples, surgically resected specimens were obtained
from ulcerative colitis (for colitis) or colorectal cancer patients (for surrounding normal colon)
who had been admitted to Hyogo College of Medicine or Kyoto University Hospital, respec-
tively. Written informed consents were obtained from all patients with the protocol approved
by the Ethics Committee of Hyogo College of Medicine or Kyoto University Graduate School
of Medicine in accordance with the ethical guidelines for epidemiological research by the Japa-
nese Ministry of Education, Culture, Sports, Science and Technology and the Japanese Ministry
of Health, Labour andWelfare as well as the principles expressed in the Declaration of
Helsinki.
Mice
Gene targeting in HK3i mouse ES cells derived from C57BL/6 embryos (Acc. No. CDB0852K:
http://www.cdb.riken.jp/arg/protocol.html) generated EPRAP/Fem1a-deficient (KO) mice.
The targeting vector was based on a modified pBluescript plasmid containing Mc1 DT-A-pA
and a floxed Pr-NEO-pA cassette, and was designed to replace the mouse Eprap/Fem1a gene
with a selection cassette (S1A Fig). PCR and Southern blot analysis identified homologous-
recombinant ES clones. Chimeric mice were generated following aggregation of the targeted
recombinant ES cells and transfer to recipient female mice. Chimeric males and C57BL/6
females were mated, and Southern blog analysis verified germline transmission and correct
gene targeting. To produce EPRAP-deficient (KO) mice, we intercrossed heterozygous off-
spring. The primers used to identify WT and deleted alleles in PCR are listed in S1 Table. WT
and KO littermates were housed individually until DSS or AOM/DSS treatment.
Mice overexpressing murine EPRAP/Fem1a under the control of the macrophage-specific
promoter CD68 [CD68–mEPRAP transgenic (TG) mice] were generated as follows. The
CD68–EPRAP/Fem1a transgene consists of the murine EPRAP/Fem1a cDNA downstream of
the mouse CD68 promoter, which was derived from pDRIVE-mCD68 (InvivoGen, San Diego,
CA, USA). We microinjected the transgene into fertilized C57BL/6 mouse eggs, and three lines
were established from six founders. PCR, using a set of two primers (S1 Table), validated trans-
genic offspring. CD68-positive bone marrow cells were sorted by staining with FITC-labeled
anti-CD68 antibody (BioLegend, San Diego, CA, USA), and quantitative PCR measured mouse
EPRAP mRNA concentrations in each line. Mice with the highest level of EPRAP expression
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were bred to C57BL/6 mice to obtain heterozygous TG mice and WT littermates and used for
the experiments described in this article.
Colitis and colitis-associated tumorigenesis
For DSS-induced colitis, 8–10-week-old male WT, KO, and TG mice were given 2.5% (w/v)
DSS (mol wt, 36,000–50,000; MP Biomedicals, Irvine, CA, USA) in their drinking water for 5
days, followed by a recovery period with regular drinking water through the end of the experi-
ment (day 21). Control mice received DSS-free drinking water. For AOM/DSS-induced inflam-
matory tumorigenesis, 8–10-week-old male WT, KO, and TG mice received intraperitoneal
injection of 12 mg/kg AOM (Sigma-Aldrich, St. Louis, MO, USA) before three cycles of DSS
administration as described above. All mice were maintained on food and water ad libitum,
and were age-matched as well as co-housed for all experiments.
Administration of EP4 agonist
Eight- to ten-week-old male WT and EPRAP-deficient (KO) mice were each divided into two
groups, EP4 agonist–treated and vehicle-treated. All four groups of mice (EP4 agonist–treated
WT, vehicle-treated WT, EP4 agonist–treated KO, and vehicle-treated KO) received 2.5% (w/
v) DSS in their drinking water ad libitum for 7 days [5]. Mice consumed either 100 μg/kg of
ONO-AE1-329 (Ono Pharmaceutical Co. Ltd., Osaka, Japan) or vehicle daily via the transanal
route for 8 consecutive days, starting the day before DSS administration.
Generation of bone marrow chimeric mice
Four- to eight-week-old male C57BL/6 wild type (WT) or EPRAP-deficient (KO) recipient
mice were irradiated with X-rays (10 Gy) and injected intravenously with 6–14×106 bone mar-
row cells derived from femurs and tibias of adult WT or KO mice. Quantitative PCR verified
peripheral blood chimerism: circulating blood cells were isolated and EPRAP mRNA expres-
sion was determined (see RNA isolation and quantitative PCR).
Antibodies and histopathological and immunohistochemical analyses
Rabbit polyclonal antibody against mouse EPRAP was raised by immunization with keyhole
limpet hemocyanin–conjugated synthetic peptides corresponding to amino-acid residues 244–
260, 330–346, and 629–645 of murine EPRAP. For immunohistochemistry of mouse samples,
paraffin-embedded sections were routinely stained with one of the following antibodies: rat
anti-F4/80 (Abcam, Cambridge, MA, USA), rat anti–Gr-1 (eBioscience, San Diego, CA, USA),
rat anti-B220 (eBioscience), rat anti-CD4 (eBioscience), rat anti-CD8 (Abcam), hamster anti-
CD11c (eBioscience), mouse anti-NCAM (Abcam), rabbit anti–phospho-NF-κB p105
(Ser933) (Cell Signaling, Boston, MA, USA), rabbit anti–phospho-MEK1/2 (Ser221) (Cell Sig-
naling), or rabbit anti–phospho-p44/42 MAPK (Thr202/Tyr204) (Cell Signaling), or rabbit
anti-EPRAP.
For immunohistochemistry of human samples, paraffin-embedded sections were stained
with rat anti-CD68 (Abcam), goat anti-FEM1A (Abcam), and rabbit anti–phospho-NF-κB
p105 (Ser933), rabbit anti–phospho-MEK1/2 (Ser221), or rabbit anti–phospho-p44/42 MAPK
(Thr202/Tyr204) antibodies. Staining with non-immune rat or rabbit IgG served as a negative
control for each experiment.
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Histological assessment of mouse colitis
A validated scoring scheme assessed colitis. In brief, histological scoring was based on three
parameters. Inflammation severity was scored as follows: 0, none; 1, mild; 2, moderate; 3,
severe. Inflammation extent was scored as follows: 0, none; 1, mucosa; 2, mucosa and submu-
cosa; 3, transmural. Crypt damage was scored as follows: 0, none; 1, basal 1/3 damaged; 2, basal
2/3 damaged; 3, crypts lost, surface epithelium present; 4, crypts and surface epithelium lost.
Inflammation severity score, inflammation extent score, and crypt damage score were each
multiplied by percent involvement (0, 0%; 1, 1–25%; 2, 26–50%; 3, 51–75%; 4, 76–100%), and
the resultant products were summed to yield a histological score ranging from 0 to 40.
Clinical parameters of ulcerative colitis patients
Disease severity was determined based on the guidelines for the management of ulcerative coli-
tis in Japan (modification of Truelove andWitts’ criteria) proposed by the Research Committee
of Inflammatory Bowel Disease [26]. The severity criteria is listed in S1 Table.
TUNEL assay
To detect apoptotic cells, paraffin-embedded sections were stained using the ApopTag in situ
apoptosis detection kit (Millipore, Billerica, MA, USA). Five different areas per tissue section
were analyzed using BZ-H2C (Keyence, Osaka, Japan).
Quantitative determination of cAMP
Peritoneal macrophages or colonic epithelial cells were harvested from 8-week-old WT, KO,
and CD68–mEPRAP transgenic (TG) mice, and 3×105 cells were seeded into individual wells
of a 96-well dish. After 10-minute treatment with different concentration of ONO-AE1-329 or
vehicle, intracellular cAMP levels were determined using the Cyclic AMP EIA Kit (Cayman
Chemical).
Cytometric bead assay and ELISA
Colonic tissues were removed and homogenized in 1% NP-40 supplemented with protease
inhibitor cocktail and PhosSTOP (Roche Diagnostics, Indianapolis, IN, USA). The BD CBA
assay (BD Bioscience, San Jose, CA, USA) measured quantitative determinations of TNF-α, IL-
6, and MCP-1 concentrations in the supernatants of tissue homogenates. Quantikine ELISA
Immunoassay (R&D Systems, Minneapolis, MN, USA) measured IL-1β and CXCL1
concentrations.
Myeloperoxidase activity
The Myeloperoxidase (MPO) Activity Colorimetric Assay Kit (BioVision, Inc., Milpitas, CA,
USA) measured MPO activity. MPO activity was compensated by the protein concentration of
lysates.
Phosphorylation assay (colonic tissues)
Lysates of colonic tissue extracts from DSS-treated WT and KOmice were assayed at a protein
of 0.5 mg/ml or 0.05 mg/ml with the PathScan Signaling Nodes Multi-Target Sandwich ELISA
Kit (Cell Signaling) according to the manufacture’s protocol.
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Phosphorylation assay (peritoneal macrophages)
Peritoneal macrophages were harvested from 10–12-week-old WT and KOmice and 1.5×106
cells were seeded into individual wells of 48-well dishes. After 1 hour of treatment with 1 μg/ml
of lipopolysaccharides (E. Coli 055:B5; LPS) (Calbiochem, San Diego, CA, USA) or vehicle,
endogenous levels of phospho-MEK and phospho-ERK were determined at a protein of 0.3
mg/ml using the PathScan Phospho-MEK1 (Ser217/221) Chemiluminescent Sandwich ELISA
Kit and the PathScan Phospho-p44/42 MAPK (Thr202/Tyr204) Sandwich ELISA Kit (Cell Sig-
naling) according to the manufacture’s protocol. Immunoblot analyses were also performed
using the whole cell lysates of WT and KO peritoneal macrophages. Antibodies against phos-
pho-NF-κB p105 (Ser933), phospho-MEK1/2 (Ser217/221), MEK1/2, phospho-p44/42 MAPK
(Thr202/Tyr204), p44/42 MAPK (Erk1/2) were from Cell Signaling Technology: anti-mouse
p105/p50 antibody was from Abcom. For quantitative PCR, peritoneal macrophages were
treated with or without LPS, followed by total RNA isolation as described in the Materials and
Methods. To test the effects of pharmacologic inhibition of MEK, cells were pretreated with
U0126 (Cell Signaling) at 10 μM for 1 hour prior to LPS treatment.
Isolation of lamina propria mononuclear cells and colonic epithelial cells,
and flow-cytometry analysis
Lamina propria mononuclear cells and colonic epithelial cells were isolated as previously
described [27]. Briefly, colonic tissues were incubated in HBSS containing 5 mM EDTA and 1
mMDTT at 37°C with shaking, and then filtered through a 100-μm cell strainer (BD Biosci-
ences). Colonic epithelial cells were harvested from the sediment of the flow-through at this
step. To isolate lamina propria mononuclear cells, the remaining pre-digested colonic tissues
were minced and incubated with PBS containing 500 μg/ml of collagenase D (Roche), 500 μg/
ml of DNase I (Sigma-Aldrich), and 3 mg/ml of dispase II (Eidia, Ibaraki, Japan) at 37°C with
shaking. After removing all remaining cell clumps by passing the suspension through a 40-μm
cell strainer (BD Biosciences), cells were resuspended with 3% (v/v) FCS in PBS. CD45+CD11b-
+ macrophages were isolated using a FACSAria II flow cytometer (BD Biosciences), following
staining of cell suspensions with FITC-labeled anti-CD45 (eBioscience) and PerCP–Cy5.5-la-
beled anti-CD11b (eBioscience). For analyses of the levels of phosphorylated forms of p105,
MEK and ERK, freshly isolated macrophages were fixed in 4% paraformaldehyde/PBS, per-
meabilized in 0.5% Triton X-100/PBS, and stained with rabbit anti–phospho-p105, anti–phos-
pho-MEK1/2, or anti–phospho-p44/42 MAPK antibody, followed by incubation with PE-
conjugated donkey anti-rabbit IgG (eBioscience). Flow cytometry was performed using FAC-
SAria II and analyzed using the FlowJo software (Tree Star Inc., Ashland, OR, USA).
RNA isolation and quantitative PCR
Trizol Reagent (Invitrogen) was used to extract total RNA, Superscript III (Invitrogen) was
used to synthesize single-stranded cDNA. The mRNA level for each target gene was deter-
mined by SYBR Green–based quantitative PCR using a LightCycler 480 system (Roche).
Primer sequences are shown in S2 Table. Data were normalized using GAPDH as a reference
gene. All reactions were performed in triplicate.
Knockdown of EPRAP
To knockdown endogenous EPRAP expression in colon cancer cells (DLD-1, ATCC No.:
CCL-221), we used the BLOCK–iTPol II miR RNAi Expression Vector Kit with EmGFP (Invi-
trogen). miRNA-expressing plasmids were constructed according to the manufacturer’s
EPRAP in Macrophage Inhibits Colonic Inflammation
PLOS Genetics | DOI:10.1371/journal.pgen.1005542 October 6, 2015 15 / 20
protocol. Target sequences were as follows: miR–EPRAP #1, 50-ACCAACCGAAAGCTATG-
CAAG-30; miR–EPRAP #2, 50-AAACCAACCGAAAGCTATGCA-30. We used the pcDNA6.2/
EmGFP–miR-negative control vector (miR–NC from Invitrogen) as a negative control. Plas-
mid transfection experiments were performed using Lipofectamine 2000 reagent (Invitrogen).
In vitro cell proliferation analysis
Following over expression [12] or knockdown of EPRAP, cell proliferation was measured with
the CellTiter 96 AQueous One Solution Cell Proliferation Assay (MTS; Promega, Madison,
WI). Briefly, 5 × 103 cells were seeded in 96–well plates and cultured in the growth medium
containing 10% fetal bovine serum for 0 h, 48 h, or 72 h. Then, absorbance at 492 nm was mea-
sured according to the manufacture’s protocol. All experiments were performed in octuplicate,
and the results are shown as mean ± SEM of values.
Statistics
Data are presented as means ± SEM. Statistical comparisons between groups were made using
Student’s t test or one-way ANOVA followed by Tukey-Kramer analysis. P values less than
0.05 were considered statistically significant.
Supporting Information
S1 Fig. Generation of EPRAP-deficient mice. (A) Targeting strategy for the generation of the
EPRAP-deficient strain. (B) Genotype mapping of WT (+/+), heterozygous (+/-), and homozy-
gous mutant (-/-) mice by genomic Southern blot analysis. Digestion of genomic DNA with
AseI produced an 18-kb fragment from the WT allele, and a 10-kb fragment from the mutant
allele, of the Eprap/Fem1a gene. (C) The EPRAP mRNA levels of WT (+/+), heterozygous
(+/-), and homozygous (-/-) mutant mice in normal colonic extracts were analyzed by quanti-
tative PCR (n = 3–4 each). Data represent fold induction of mRNA expression compared with
WT (+/+). (D) A specific antibody against murine EPRAP was generated. EPRAP was immu-
nostained with this antibody, using rectal sections obtained from DSS-treated WT (+/+) and
homozygous EPRAP-deficient (-/-) mice.
(TIF)
S2 Fig. EPRAP deficiency exacerbates DSS-induced colitis. (A) Immunohistochemical stain-
ing to detect F4/80, Gr-1, B220, CD4, and CD8 in rectal sections of DSS-treated WT and
EPRAP-deficient (KO) mice. (B) The mRNA levels of iNOS and CXCL10 in colonic stromal
macrophages of DSS-treated WT and KOmice (n = 7 [WT]; n = 5 [KO]). Data represent fold
induction of mRNA expression compared with WT.
(TIF)
S3 Fig. EPRAP deficiency exacerbates AOM/DSS colitis. (A)H & E staining in rectal sections
(non-polyp lesion) of AOM/DSS-treated WT and KOmice. (B) Immunohistochemical stain-
ing to detect F4/80, Gr-1, B220, CD4, and CD8 in rectal sections (non-polyp lesion) of AOM/
DSS-treated WT and KOmice. (C)Histological colitis score in rectal sections (non-polyp
lesion) of AOM/DSS-treated WT and KOmice (n = 9 [WT]; n = 5 [KO]). (D) The numbers of
F4/80-, Gr-1-, B220-, CD4-, and CD8-positive cells infiltrated in colonic tissues per high-
power field (400× magnification) in rectal sections (non-polyp lesion) of AOM/DSS-treated
WT and KOmice (n = 9 [WT]; n = 5 [KO]). All values represent means ± SEM. P< 0.05,
P< 0.01 vs. WT mice. Scale bars: 100 μm.
(TIF)
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S4 Fig. EPRAP overexpression and knockdown. (A, B) DLD-1 cells were transiently trans-
fected with V5-tagged human EPRAP expression construct or mock plasmid. Immunoblot
analysis showing the enforced expression of recombinant EPRAP (A): quantitative real-time
PCR showing increased levels of total cellular EPRAP mRNA (n = 4 each). P< 0.01 vs. mock
(B). (C) EPRAP gene knockdown experiments were performed as described in the Materials
and Methods. Testing the efficiency of the gene silencing entailed quantitative real time PCR
analysis (n = 4 each). P< 0.05 vs. negative control.
(TIF)
S5 Fig. EPRAP is present in, and deactivates, macrophages in lamina propria and submu-
cosa. (A) Immunohistochemical detection of EPRAP-expressing cells. The colonic tissues were
obtained fromWTmice subjected to no treatment (drug-free water; normal colon), DSS treat-
ment, or AOM/DSS treatment. Scale bars: 100 μm. (B) Double–color immunofluorescence
staining of rectal sections from control-, DSS-, or AOM/DSS-treated WTmice was performed
with a combination of anti-EPRAP (red) and anti-F4/80 (green) antibodies. Scale bars: 20 μm.
(C) Double–color immunofluorescence staining of rectal sections from DSS-treated WTmice
was performed using a combination of anti-EPRAP (red) and anti-CD4, anti-CD8, anti-
CD11c, anti-B220, or anti-NCAM (green) antibodies. Scale bars: 20 μm. (D) Double–color
immunofluorescence staining of rectal sections from DSS-treated WT mice was performed
using a combination of anti-EPRAP (red) and anti–Gr-1 (green) antibodies. Scale bars: 20 μm.
(E)MPO activity was measured in protein extracts from colonic tissues from DSS-treated WT
and EPRAP-deficient (KO) mice (n = 6 [WT]; n = 4 [KO]). MPO activity (left) and MPO activ-
ity compensated by the numbers of Gr-1–positive cells infiltrated in colonic tissues per high-
power field (Fig 1G) (right). (F) The mRNA levels of TNF-α, IL-1β, CXCL1, and MCP-1 in
colonic stromal macrophages of DSS-treated WT and EPRAP-deficient (KO) mice (n = 7
[WT]; n = 5 [KO]). (G) The EPRAP mRNA levels of lamina propria macrophages (LPMC)
and epithelial cells isolated from the colonic tissues of WT mice with DSS treatment. Data rep-
resent fold induction of mRNA expression compared with WT. P< 0.05, P< 0.01 vs. WT
mice.
(TIF)
S6 Fig. EP4 signaling ameliorates MEK and ERK activation through EPRAP in sromal
macrophages with DSS treatment. (A) Double-color immunofluorescence staining of rectal
sections from DSS-treated WT and EPRAP deficient mice with or without EP4 agonist treat-
ment (as described in the Fig 3 legend) was performed with anti-F4/80 (green) and anti–phos-
pho-MEK (red) (left), anti–phospho-ERK (red) (right). Scale bars: 20 μm. (B) The percentages
of phospho-MEK (left) or phospho-ERK (right) positive cells in F4/80 positive macrophages
(n = 5 each).
(TIF)
S7 Fig. The lack of EPRAP enhances lipopolysaccharide (LPS)-induced phosphorylation of
p105, MEK and ERK in peritoneal macrophages. Peritoneal macrophages were isolated from
10–12-week-old of WT or KO mice. Cells were incubated with LPS or vehicle for one hour, fol-
lowed by whole cell extraction. (A) Immunoblot analyses were performed to examine the levels
of phosphorylated forms of p105, MEK and ERK. Figures are representative of three indepen-
dent experiments. (B) The expression levels of phosphorylated forms of MEK and ERK were
examined (n = 4 each). (C) The mRNA levels of TNF-α, IL-1β, IL-6, and CXCL1 in peritoneal
macrophages of WT or KO mice (n = 7–9 each). (D) The mRNA levels of TNF-α, IL-1β, IL-6,
and CXCL1 in peritoneal macrophages of WT or KO mice pre-treated with MEK inhibitor
(U0126) (n = 6 each). Data represent fold induction of mRNA expression of LPS-treated cells
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compared with that of vehicle-treated cells. P< 0.05, P< 0.01 vs. WT mice.
(TIF)
S8 Fig. CD68-mEPRAP transgenic mice. (A) Double–color immunofluorescence staining of
rectal sections fromWT and CD68–mEPRAP transgenic (TG) mice was performed with a
combination of anti-EPRAP (red) and anti-F4/80 (green) antibodies. (B) The mRNA levels of
EPRAP in CD68-positive bone marrow cells (n = 4 each). Data represent fold induction of
mRNA expression compared with WT. P< 0.01 vs. WT mice.
(TIF)
S9 Fig. EPRAP overexpression in macrophages ameliorated cellular infiltration in DSS-
induced colitis. (A) Survival curves during the DSS treatment. WT and TG mice had no signif-
icant difference in mortality (n = 18 [WT]; n = 9 [TG]). (B) Percent changes in body weight
(n = 16 [WT]; n = 8 [TG]). WT and TG mice had no significant difference. (C) Immunohisto-
chemical staining to detect F4/80, Gr-1, B220, CD4, and CD8 in rectal sections of DSS-treated
WT and TG mice.
(TIF)
S10 Fig. EPRAP overexpression in macrophages ameliorated AOM-DSS-induced colitis.
(A)H & E staining in rectal sections (non-polyp lesion) of AOM/DSS-treated WT and TG
mice. (B) Immunohistochemical staining to detect F4/80, Gr-1, B220, CD4, and CD8 in rectal
sections (non-polyp lesion) of AOM/DSS-treated WT and TG mice. (C)Histological colitis
score in rectal sections (non-polyp lesion) of AOM/DSS-treated WT and KOmice (n = 9
[WT]; n = 8 [TG]). (D) The numbers of F4/80-, Gr-1–, B220-, CD4-, and CD8-positive cells
infiltrated in colonic tissues per high-power field (400× magnification) in rectal sections (non-
polyp lesion) of AOM/DSS-treated WT and TG mice (n = 9 [WT]; n = 8 [TG]). All values rep-
resent means ± SEM. P< 0.01 vs. WT mice. Scale bars: 100 μm.
(TIF)
S11 Fig. p105 phosphorylation and MEK-ERK activation in EPRAP-positive cells in the
colons of human ulcerative colitis (UC) patients. (A) Double–color immunofluorescence
staining of colonic sections of UC patients was performed with a combination of anti-EPRAP
(green) and anti–phospho-p105 (red, top), anti–phospho-MEK (red, middle), or anti–phos-
pho-ERK (red, bottom) antibodies. Scale bars: 20 μm.
(TIF)
S1 Table. The criterion for severity of ulcerative colitis.
(DOCX)
S2 Table. Primers used in this study.
(DOCX)
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